Anti-Coagulants - Oman

Oman

The Anti-Coagulants market in Oman is expected to witness a significant increase in revenue, reaching a projected value of US$11.58m in 2024.
This growth is anticipated to continue at a compound annual growth rate (CAGR) of 7.89% from 2024 to 2029, leading to a market volume of US$16.93m by the end of 2029.
When considering the global landscape, it is noteworthy that United States is projected to generate the highest revenue in the Anti-Coagulants market, with an estimated value of US$16,740.00m in 2024.
"The demand for anti-coagulants in Oman is steadily increasing due to the rising prevalence of cardiovascular diseases in the country."

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Coagulants in Oman has been on the rise in recent years, driven by various factors.

Customer preferences: Patients in Oman are increasingly opting for Anti-Coagulants as a form of treatment for blood clots and related conditions. This is due to the effectiveness of these drugs in preventing the formation of blood clots, which can lead to serious health complications.

Trends in the market: One of the key trends in the Anti-Coagulants market in Oman is the growing popularity of direct oral anticoagulants (DOACs). These drugs have gained traction in recent years due to their ease of use and lower risk of complications compared to traditional Anti-Coagulants such as warfarin. Additionally, there has been a shift towards outpatient treatment, with more patients receiving Anti-Coagulant therapy in the comfort of their homes.

Local special circumstances: The high prevalence of cardiovascular disease in Oman has contributed to the growth of the Anti-Coagulants market. The country has one of the highest rates of heart disease and stroke in the world, which has led to an increased demand for Anti-Coagulants among the population.

Underlying macroeconomic factors: The Omani government has been investing heavily in the healthcare sector, which has led to improved access to medical services and increased awareness of various health conditions. This has contributed to the growth of the Anti-Coagulants market in the country. Additionally, the aging population in Oman has also led to an increased demand for Anti-Coagulants, as older individuals are more susceptible to blood clots and related conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.